We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Platelet Membrane-Coated Nanoparticles Kill Circulating Tumor Cells and Prevent Metastasis in Breast Cancer Model

By LabMedica International staff writers
Posted on 25 Nov 2015
Silica nanoparticles functionalized with activated platelet membranes along with surface conjugation of the tumor-specific apoptosis-inducing ligand cytokine TRAIL were shown to facilitate the destruction of circulating tumor cells (CTCs) and prevent the spread of the disease in a mouse breast cancer metastasis model.

Investigators at Cornell University (Ithaca, NY, USA) had shown in previous studies that (CTCs) became part of a "microenvironment" when they became physically associated with activated platelets and fibrin while being transported in the bloodstream.

To attack the tumor cells within this microenvironment, the investigators prepared synthetic silica nanoparticles coated with proteins from activated platelet membranes. More...
Molecules of the cytokine TRAIL (tumor necrosis factor related apoptosis-inducing ligand) were attached to the surface of the particles.

TRAIL is a cytokine that is produced and secreted by most normal tissue cells. It causes apoptosis primarily in tumor cells by binding to certain death receptors. Since the mid-1990s it has been used as the basis for several anti-cancer drugs, but had not been found to have any significant survival benefit.

The investigators reported in the October 21, 2015, online edition of the journal Biomaterials that their synthetic nanoparticles attached to "natural killer cells" in the blood which then became incorporated into CTC-associated micro-thrombi in blood vessels within the lungs. The ramped-up killer cells acted to dramatically decrease lung metastases in a mouse breast cancer metastasis model.

"In our research, we use nanoparticles— the liposomes we have created with TRAIL protein—and attach them to natural killer cells, to create what we call "super natural killer cells" and then these completely eliminate lymph node metastases in mice," said senior author Dr. Michael R. King, professor of biomedical engineering at Cornell University. "So, now we have technology to eliminate bloodstream metastasis—our previous work—and also lymph node metastases."

Related Links:

Cornell University




New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.